Research

Mixed

The cardiovascular benefits of soy isoflavones, particularly regarding blood pressure and inflammation, are conditional on the individual's ability to metabolize daidzein into equol via gut microbiota.

If you eat soy and see no heart health benefits, you might be a 'non-producer' of equol. This is determined by your gut bacteria. While soy is still healthy, its specific blood-pressure-lowering power is mostly reserved for those who can convert it to equol.

GoodConditionalMEDIUM confidence
There is emerging evidence on the diverging biological effects among individuals capable of metabolizing the soy isoflavone daidzein to the more bioactive metabolite equol... blood pressure, plasma triglycerides (TG) and C-reactive protein (CRP) concentrations were significantly lowered among equol- and O-desmethylangolensin (ODMA)-producing pre-hypertensive, postmenopausal Chinese women, compared to non-producers
D. Dan Ramdath et al. · Nutrients · 2017

Why this rating

Consistent observational and some interventional data support the equol-producer advantage, though large-scale RCTs are fewer.

Source

Beyond the Cholesterol-Lowering Effect of Soy Protein: A Review of the Effects of Dietary Soy and Its Constituents on Risk Factors for Cardiovascular Disease

D. Dan Ramdath et al. · Nutrients · 2017

DOI 10.3390/nu9040324

narrative_reviewCited 261×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →